Overexpression of CRM1 is seen in numerous malignancies, including leukemias, lymphomas, neuroblastomas, gastric, pancreatic, melanoma, and lung cancers, and is often associated with poor prognosis [21–28]. Here, XPO1 is linked to neuroblastoma.